Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse i pædiatriske deltagere i alderen ≥2 til <12 år med en mistænkt eller bekræftet bakteriel infektion eller som modtager profylaktiske antibiotika

25. september 2026 opdateret af: GlaxoSmithKline

Fase 1, åben-label, enkelt-arm (ikke-komparativ) undersøgelse for at evaluere farmakokinetikken og sikkerheden af en enkelt dosis oral gepotidacin udover standardantibakteriel behandling hos børnedeltagere fra 2 til under 12 år med mistanke om eller bekræftet bakteriel infektion eller som modtager profylakse med antibiotika

The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment with antibacterials for a confirmed or suspected infection or for its prevention.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

25

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

  • Forenede Stater
    • California
      • Orange, California, Forenede Stater, 92868
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Antonio Arrieta
    • Louisiana
      • Shreveport, Louisiana, Forenede Stater, 71101
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Patricia Pichilingue-Reto
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21827
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Allison Agwu
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110-1010
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • David Hunstad

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år til 11 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participants having ≥2 to <12 years of age at the time of signing the informed consent/assent and have a body weight >=10 kilograms (kg).
  • Participants receiving SoC antibacterial therapy for a confirmed/suspected infection or for prophylaxis AND is able to take a single dose of the powder for oral suspension formulation of gepotidacin after a meal.
  • Participants either hospitalized or in an overnight clinic. Participant is expected to be in hospital/clinic for at least 24 hours post administration of study intervention.

Participant has an indwelling venous catheter in place as part of the clinical SoC.

  • Male or female according to their reproductive organs at birth.
  • Pregnancy testing is required as appropriate for the age, sexual activity, and sexual maturity of pediatric participants and as required by local regulations. Investigator should apply clinical judgment.
  • A female participant is eligible to participate if she is a WOCBP who is not pregnant as confirmed by a high sensitivity serum or urine pregnancy test at baseline (Day 1) regardless of current or prior contraception use or abstinence, is not breastfeeding, or is not a WOCBP.
  • Participant LAR(s) who has the ability to understand, agree to, and sign the informed consent form before initiation of any protocol-related procedures; participant has the ability to give documented assent.
  • Participant and participant's LAR are willing and able to comply with study instructions, study visits, and procedures.

Exclusion Criteria:

  • Participants having a BMI-for-age that is less than the 5th percentile or greater than the 95th percentile based on the CDC percentiles [CDC NCHS Growth Charts].

  • Participants having a clinically significant medical history, including malignancy, significant chromosome abnormality, neurological disorder or history of seizure (excluding simple febrile seizure), chronic immunosuppressive disease, active tuberculosis or acute hepatitis.

  • Participants with serious disease/condition that could be imminently life-threatening (e.g. is clinically/hemodynamically unstable, is septicemic, has severe sepsis, organ failure, requiring ITU care or has clinical laboratory tests either nonstable or anticipated to be nonstable) or the participant is unlikely to survive for the duration of the study period.

  • The participant has severe renal organ dysfunction or has known anuria, oliguria, or significant impairment of renal function (creatinine clearance <60 mL/min or clinically significant elevated serum creatinine as determined by the investigator).

  • The participant has a significant CV history or based on investigator judgment any clinically significant abnormal ECG reading at Screening/baseline (e.g., prolonged QT syndrome).

  • The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of complications (e.g., uncontrolled diabetes in the judgment of the investigator, transplant recipients (with the exception of cornea and autologous BMT), participants with clinically significant persistent granulocytopenia [absolute neutrophil count <1000/μL], and participants receiving immunosuppressive therapy, including corticosteroid therapy at a dose of >1 mg/kg/day of prednisolone or equivalent for >1 week or 0.5-<1 mg/kg/day prednisolone or equivalent for >2 weeks). Participants aged ≥6 years with a known CD4 count of <200 cells/mm3 and participants aged <6 years with a known CD4 count of <500 cells/mm3 are to not be enrolled.

  • The participant has any of the following medical condition that requires medication that may be impacted by inhibition of acetylcholinesterase, such as:

    • Poorly controlled asthma or obstructive pulmonary disease at baseline and, in the opinion of the investigator, not stable on current therapy.
    • Active peptic ulcer disease
    • Juvenile Parkinson disease
    • Juvenile Myasthenia gravis

  • The participant has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention (e.g., ileostomy or malabsorption syndrome).

  • The participant plans to use any of the prohibited medications or nondrug therapies from the Baseline Visit through Follow-up Visit at 7 ±3 days after the single dose of study intervention.

  • The participant has received a prohibited medication within 14 days or 5 half-lives prior to gepotidacin administration, whichever is longer.

  • The participant has been previously enrolled in this study or has previously been treated with gepotidacin.

  • The participant has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives prior to gepotidacin administration, whichever is longer.

  • The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.

  • If the child is being breastfed:

    • There is suspicion of current alcohol or substance misuse/abuse in breastfeeding mother.
    • The breastfeeding mother is taking any medication or any substances containing any of the medications included in the prohibited medication list with known or unknown lactation excretion.

  • The participant has severe hepatic organ dysfunction.

  • The participant has an ALT value >2 × ULN.

  • The participant has a total bilirubin >1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is ≤1.5xULN.

  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.

  • The participant has congenital long QT syndrome or known prolongation of the QTc interval.

  • The participant has uncompensated heart failure.

  • The participant has severe left ventricular hypertrophy.

  • The participant has a family history of QT prolongation or sudden death or history of sudden infant death in a sibling.

  • The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.

  • The participant is taking QT-prolonging drugs or drugs known to increase the risk of TdP per the ww.crediblemeds.org. "Known Risk of TdP" category at the time of the Baseline Visit, which cannot be safely discontinued from the Baseline Visit (Day 1) through 7 (+3) days after the single dose of study intervention; or the participant is taking a strong CYP3A4 inhibitor.

  • The participant has a mean triplicate QTc >450 msec or a mean triplicate QTc >480 msec for participants with complete bundle branch block.

  • The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Gepotidacin plus Standard of care (SOC)

Single Arm
Medicin: Gepotidacin

Gepotidacin will be administered

Medicin: SOC

SOC will be administered

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
AUC fra tid nul til tidspunktet for den sidste kvantificerbare koncentration (AUC[0-t]) af gepotidacin
Tidsramme: Op til 24 timer efter dosis (dag 1)
Op til 24 timer efter dosis (dag 1)
Areal under koncentrationstidskurven fra tid nul ekstrapoleret til uendelig tid (AUC[0-inf]) for gepotidacin
Tidsramme: Op til 24 timer efter dosering (dag 1)
Op til 24 timer efter dosering (dag 1)
Maksimalt observeret plasmakoncentration (Cmax) for gepotidacin
Tidsramme: Op til 24 timer efter dosering (dag 1)
Op til 24 timer efter dosering (dag 1)
Tilsyneladende oral clearance (CL/F) af gepotidacin
Tidsramme: Op til 24 timer efter dosering (dag 1)
Op til 24 timer efter dosering (dag 1)
Tilsyneladende distributionsvolumen (Vz/F) for gepotidacin
Tidsramme: Op til 24 timer efter dosering (dag 1)
Op til 24 timer efter dosering (dag 1)
Terminal fase halveringstid (t1/2) for gepotidacin
Tidsramme: Op til 24 timer efter dosering (dag 1)
Op til 24 timer efter dosering (dag 1)

Sekundære resultatmål

Resultatmål
Tidsramme
Antal deltagere med bivirkninger (AEs), særligt interesserende bivirkninger (AESI) og alvorlige bivirkninger (SAEs)
Tidsramme: Op til 7 dage (±3 dage)
Op til 7 dage (±3 dage)
Ændring fra baseline i vitale tegn: Temperatur
Tidsramme: 2 timer (±15 minutter) efter dosis på dag 1
2 timer (±15 minutter) efter dosis på dag 1
Ændring fra baseline i vitale tegn: Blodtryk
Tidsramme: 2 timer (±15 minutter) efter dosering på dag 1
2 timer (±15 minutter) efter dosering på dag 1
Ændring fra baseline i vitale tegn: Pulsfrekvens
Tidsramme: 2 timer (±15 minutter) efter dosering på dag 1
2 timer (±15 minutter) efter dosering på dag 1
Ændring fra baseline i Elektrokardiogram (ECG)
Tidsramme: Ved 2 timer (±15 minutter) efter dosering på dag 1
Ved 2 timer (±15 minutter) efter dosering på dag 1

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

GlaxoSmithKline

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

18. september 2026

Primær færdiggørelse (Anslået)

23. august 2027

Studieafslutning (Anslået)

23. august 2027

Datoer for studieregistrering

Først indsendt

19. januar 2026

Først indsendt, der opfyldte QC-kriterier

19. januar 2026

Først opslået (Faktiske)

28. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 222778
  • 2025-522916-17 (EudraCT nummer)
  • 2025 (U.S. NIH-bevilling/kontrakt)
  • HSSO100201300011C (Anden identifikator: BARDA Agreement number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD-delingsadgangskriterier

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner